Compare HLX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | PVLA |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1996 | N/A |
| Metric | HLX | PVLA |
|---|---|---|
| Price | $9.50 | $156.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $11.50 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.7M | 276.7K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $876,561,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $5.46 | $104,350.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $29.59 |
| 52 Week High | $10.75 | $161.38 |
| Indicator | HLX | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 63.83 |
| Support Level | $9.43 | $106.07 |
| Resistance Level | $9.89 | $156.28 |
| Average True Range (ATR) | 0.25 | 10.12 |
| MACD | 0.12 | 0.36 |
| Stochastic Oscillator | 85.89 | 80.10 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.